PMCB Stock, PharmaCyte Biotech Inc. Information

PharmaCyte is a clinical stage biotechnology company developing therapies for cancer and diabetes based upon a proprietary cellulose based live cell encapsulation technology known as Cell in a Box. This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed. For cancer, the therapy involves encapsulating genetically engineered human cells that convert the prodrug ifosfamide from its inactive form to its cancer killing form. These encapsulated live cells are implanted in a patient as close to the tumor as possible. Then ifosfamide is given IV at one third the normal dose. When the ifosfamide comes in contact with the encapsulated live cells, they act as an artificial liver where ifosfamide is normally activated and activate the ifosfamide at the source of the cancer. For diabetes, PharmaCyte is developing a treatment for Type diabetes and insulin dependent Type diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. PharmaCyte is also exploring the use of beta islet cells to treat Type and insulin dependent Type diabetes. The encapsulation of these cells will be done using the Cell in a Box technology. Once the encapsulated cells are implanted in a diabetic patient they will function as a bio artificial pancreas for purposes of insulin production.